Skip to main content

Table 2 Baseline Characteristics and pCR Rates of the SpheroNEO cohort

From: Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study

  pCR  
  All Patients Yes No  
Characteristics n % n % n % P
All Patients 78 100 22 28.2 56 71.8  
Age at diagnosis, years   .207
  ≤50 43 55.1 15 34.9 28 65.1  
  >50 35 44.9 7 20.0 28 80.0  
Mean 51 21 - 78 46 21 - 65 53 25 - 78 .029
Range
Tumor stage   .779
  cT1/T2 56 72.7 16 28.6 40 71.4  
  cT3/4 21 27.3 5 23.8 16 76.2  
  Not documented 1 -      
Nodal status   1.000
  cN+ 42 54.5 12 28.6 30 71.4  
  cN- 35 45.5 10 28.6 25 71.4  
  Not documented 1 -      
Grading   .123
  G1/2 41 53.9 8 19.5 33 80.5  
  G3 35 46.1 13 37.1 22 62.9  
  Not documented 2 -      
Histologic type   .449
  Invasive ductal/other 70 89.7 21 30.0 49 70.0  
  Invasive lobular 8 10.0 1 12.5 7 87.5  
HR status   .001
  ER+/PR+ 39 52.0 4 10.3 35 89.7  
  ER+/PR-/Unknown 10 13.3 7 70.0 3 30.0  
  ER-/unknown/PR+ 2 2.7 1 50.0 1 50.0  
  ER-/PR- 24 32.0 9 37.5 15 62.5  
  Not documented 3 -      
HER2 status   .001
  Negative 59 78.7 11 18.6 48 81.4  
  Positive 16 21.3 10 62.5 6 37.5  
  Not documented 3 -      
Drug Therapy   .001
  AC → T 57 71.8 11 19.3 46 80.7  
  AC → TH 9 11.5 8 88.9 1 11.1  
  TCbH 7 9.0 2 28.6 5 71.4  
  AC → TCb 3 3.8 1 33.3 2 66.7  
  AC 2 3.6 0 0.0 2 100.0  
Treatment adherence   .018
  Yes 60 76.9 21 35.0 39 65.0  
  No 18 23.1 1 5.6 17 94.4  
  1. Statistical tests for categorical factors were performed using the Pearson’s Χ2 test or Fisher’s exact test; tests for numerical factors were performed using a t-test
  2. PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor; pCR, pathologic complete response; A, anthracycline, T, paclitaxel or docetaxel, C, cyclophosphamide; Cb, carboplatin, H, trastuzumab